Primary testicular lymphoma is an uncommon testicular tumour. We present a case ora primary non-Hodgkin lymphoma of the testis, describing its clinical and pathological features and discussing our treatment strategy. A 68-year-old man showed a firm erythematous testicular mass within the right emiscrotum. Subsequent ultrasonography demonstrated a right inferior pole testicular mass with disomogenously hypoecogenic. The patient was submitted to inguinal orchidectomy. Light microscopy demonstrated the classic appearance of a diffuse large B-cell lymphoma. The immunohistochemical study showed tumour cells intensively positive for CD45, Ki67 and CD20. No evidence of extra-testicular involvement by lymphoma was found. At 6 months, a TC-PET showed a clinical relapse in lung and abdominallymphonodes, while clinical examination demonstrated a single, indolent and erythematous nodule in the left foot. The histologic analysis confirmed diagnosis of CD-20 positive B-celllymphoma. The patient was treated with an anti-CD 20 monoclonal antibody (rituximab) alone every 3 weeks. After 3 months a complete response was observed in all sites of disease. The patient was free from disease at 12 months follow-up.
Primary testicular lymphoma is an uncommon testicular tumour that accounts for no more than 9% of all testicular tumours. As haematopoietic tumour it is also rare, accounting for just 1% of all lymphomas, the dominant subtype being the diffuse large B-cell type (I).
Patient age at presentation is over 60 years which makes it the most frequent tumour for this age group (2) . Due to their highly malignant histopathology they may become highly aggressive tumours, there is no standard protocol to treat this malignancy due to lack of extensive series (3).
We present a case of a primary non-Hodgkin lymphoma of the testis, describing its clinical and pathological features and discussing our treatment strategy.
MATERIALS AND METHODS

Clinical presentation and diagnosis
A 68-year-old man with a previous history of heart disease and liver dysfunction presented with a testicular swelling. He reported no further systemic symptoms. Clinical examination showed a firm erythematous testicular mass within the right emiscrotum. Subsequent ultrasonography demonstrated a right inferior pole testicular mass with disomogenously hypoecogenic. irregular shape invaded the inferior pole of the testis and focally the epididymis ( Fig. 1 ).
Light microscopy demonstrated sheets of lymphoma cells involving epididymis and rete testis, but mainly extended into testicular parenchyma. Malignant cells were large with scant cytoplasm and large vesicular nuclei, the classic appearance of a diffuse large B-cell lymphoma. An immunohistochemical study was carried out on paraffin embedded sections of surgical specimen. The following antibodies were applied for immunophenotypic examination: LCA (CD45; 1:100), L26 (CD20; 1:200); CD3 (clone F7.2.38; I: 50), CD30 (clone Ki-l; 1:40); Ki67 (MIB-l; 1:100). Tumour cells were intensively positive for CD45, Ki67 and CD20 (Fig. 2) .
After the pathological diagnosis, the patient completed the clinical staging for lymphoma. No evidence of extra-testicular involvement by lymphoma was found.
Follow-up
At 6 months, a TC-PET showed a clinical relapse in lung and abdominal lymph nodes (Fig. 3) . Clinical examination demonstrated a single, indolent and erythematous nodule, 1.5 em of diameter, localized to the left foot. The histologic and immunophenotype analysis confirmed diagnosis of B-cell lymphoma, CD 20 positive. All sites were considered secondary to primary lymphoma of testis.
The patient was treated with an anti-CD 20 monoclonal antibody, rituximab, alone every 3 weeks. After 3 months a complete response was observed in all sites of disease ( Fig. 4) , including the 
RESULTS
The patient was submitted to right inguinal orchidectomy. The testis measured 5.5 x 5.5 ern. A tan-white hardened mass of 3 ern in diameter with disappearance of cutaneous nodule. The patient was free from disease at 12 months follow-up.
DISCUSSION
Testicular lymphoma may be the primary and only manifestation of malignant lymphoma, the initial sign of generalized disease, or may occur during the course of a patient with established lymphoma (4) . It is locally aggressive, typically infiltrating the epididymis, as in our case, the spermatic cord or the scrotal skin (l).
The imaging features of testicular lymphoma reflect its infiltrative characteristics as seen at pathologic examination (5) . At ultrasonography, the normal omogeneous ecogenic testis is replaced with hypoecoic vascular lymphomatous tissue. Lymphoma typically infiltrates the epididymis, which then becomes enlarged and hypoechoic (5) .
The differential diagnosis includes epididymoorchitis, sarcoid, lymphoma, tuberculosis and leukaemia. Testicular germ-cell tumors are not included as they appear more lobulated with welldefined borders at ultrasonography, and rarely involve both the testis and epididymis (5) .
Immunohistochemical staining of malignant cells is of utmost importance for the evaluation of the neoplasm, providing data on their lymphomatous origin (6) . In general, most of the reported cases are of a B-celliineage. In such cases, specific phenotypic markers (C045; C020; C03; C030) confirm the final diagnosis (6) .
The prognosis of testicular lymphoma remains poor. Patients who are treated for primary testicular lymphoma usually demonstrate widespread dissemination within the first 2 years. The 5-year survival rate is about 12%, with a median survival time ofless than 12 months (4) .
The data and experience available to guide treatment strategies are limited and mostly based on observational retrospective or population-based studies involving small cohorts of patients. However, available evidence suggests a combined modality approach being the most likely effective treatment, comprising surgery, antracycline-containing combination chemotherapy with or without prophylactic controlateral testis and regional lymph node irradiation (3).
Our patient was treated with rituximab after which the disease completely cleared up. Rituximab is a chimeric anti-C020 human immunoglobulin G I monoclonal antibody approved for treatment of recurrent follicular lymphoma (7) . We used rituximab alone, without chemotherapy, for the age and concomitant co-morbidities of the patient. Surely, this agent can represent a good option of treatment in testicular lymphoma, especially in older patients.
